News
VTVT
14.96
+3.03%
0.44
Weekly Report: what happened at VTVT last week (1209-1213)?
Weekly Report · 5d ago
Tracking Baker Brothers Portfolio - Q3 2024 Update
Seeking Alpha · 12/12 04:38
vTv Therapeutics Price Target Announced at $35.00/Share by Alliance Global Partners
Dow Jones · 12/09 17:08
vTv Therapeutics initiated with a Buy at Alliance Global Partners
TipRanks · 12/09 12:36
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
Reuters · 12/09 12:33
Weekly Report: what happened at VTVT last week (1202-1206)?
Weekly Report · 12/09 12:27
VTV THERAPEUTICS INC <VTVT.O>: ALLIANCE GLOBAL PARTNERS INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $35
Reuters · 12/09 12:19
U.S. RESEARCH ROUNDUP-Cheniere Energy, Redwood Trust, Verisign
Reuters · 12/09 07:01
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
Barchart · 12/02 15:05
Weekly Report: what happened at VTVT last week (1125-1129)?
Weekly Report · 12/02 12:28
Weekly Report: what happened at VTVT last week (1118-1122)?
Weekly Report · 11/25 12:15
Weekly Report: what happened at VTVT last week (1111-1115)?
Weekly Report · 11/18 12:11
vTv Therapeutics GAAP EPS of -$0.88
Seeking Alpha · 11/13 07:10
vTv Therapeutics Q3 EPS $(0.88) Up From $(3.19) YoY
Benzinga · 11/12 22:14
*VTv Therapeutics 3Q Rev $0.00 >VTVT
Dow Jones · 11/12 22:07
*vTv Therapeutics 3Q Loss/Shr 88c >VTVT
Dow Jones · 11/12 21:05
Press Release: vTv Therapeutics Announces 2024 -2-
Dow Jones · 11/12 21:05
VTv Therapeutics: Q3 Earnings Snapshot
Barchart · 11/12 16:03
Weekly Report: what happened at VTVT last week (1104-1108)?
Weekly Report · 11/11 12:32
Weekly Report: what happened at VTVT last week (1028-1101)?
Weekly Report · 11/04 12:26
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.